Cimpuciclib (example 63, 50 mg/kg, oral gavage, twice a week) inhibits tumor growth in colo205 tumor-bearing mice[1].
Cimpuciclib (5 mg/kg for rats, 50 mg/kg for colo205 tumor-bearing mice, oral administration) shows slow metabolic rate and maintains high concentration in the plasma[1].
| Animal Model: | Colo205 tumor-bearing mice[1] |
| Dosage: | 50 mg/kg, twice a week |
| Administration: | Oral gavage |
| Result: | Inhibited tumor growth by 93.63%. |
| Animal Model: | Rats, colo205 tumor-bearing mice[1] |
| Dosage: | 5 mg/kg for rats, 50 mg/kg for colo205 tumor-bearing mice. |
| Administration: | Oral administration |
| Result: | Pharmacokinetic profile of Cimpuciclib (example 63).
| dose (mg/kg) | Cmax (ng/mL) | Tmax (h) | AUC0-24 (ng/mL?h) | t1/2 (h) | |
| 5 mg/kg (rats) | 559.7 | 6 | 5414 | 2.4 | |
| 50 mg/kg (mice) | 7960 | 1 | 136782 | 14.8 |
|
